STOCK TITAN
  1. Home
  2. News
  3. SRNEQ

Sorrento Therapeutics, Inc. - $SRNEQ STOCK NEWS

Welcome to our dedicated page for Sorrento Therapeutics news (Ticker: $SRNEQ), a resource for investors and traders seeking the latest updates and insights on Sorrento Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sorrento Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sorrento Therapeutics's position in the market.

News
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Rhea-AI Summary
Sorrento Therapeutics completes sale of securities to Scilex Holding Company for $110 million, losing controlling interest over Scilex. Oramed SPA terminated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Rhea-AI Summary
Sorrento Therapeutics announces positive Phase 3 results for Ovydso as a standalone treatment for COVID-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
clinical trial covid-19
-
News
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Rhea-AI Summary
Sorrento Therapeutics announces positive Phase 2a results for the RTX program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40%
Tags
clinical trial
News
Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid
Rhea-AI Summary
Sorrento Therapeutics, Inc. (OTC: SRNEQ) announces approval of $105 million 'stalking horse' bid for Scilex Holding Company by Oramed Pharmaceuticals, Inc. in connection with ongoing chapter 11 case.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
Rhea-AI Summary
Sorrento Therapeutics has posted a FAQ document regarding its offering of restricted stock of Scilex Holding Company. The document addresses questions about the process and mechanics of purchasing the stock, both in open market purchases and private transactions. The shares will be subject to a lock-up restriction expiring on September 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
dividends
-
News
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
clinical trial
News
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Rhea-AI Summary
Sorrento Therapeutics has completed the enrollment of a pivotal Phase 3 study for its oral Mpro inhibitor, Ovydso, in mild or moderate symptomatic adults infected with COVID-19. The study enrolled 1,200 patients in China and is expected to have top line data in the third quarter of this year. If successful, Sorrento plans to open discussions with regulatory authorities worldwide for approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
News
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
Rhea-AI Summary
Sorrento Therapeutics has been awarded a $4.6 million contract from the National Institute of Allergy and Infectious Diseases for the development of in vitro diagnostics for biodefense and emerging infectious diseases. The contract aims to develop a diagnostic platform for rapid and sensitive detection of proteins and other biomolecules, improving existing testing devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News
Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts
Rhea-AI Summary
Sorrento Therapeutics announces that the U.S. Bankruptcy Court has ordered brokerage firms to credit all shares of Scilex Holding Company to customers' accounts. The court also requires the firms to report the number of shares and quoted price of the stock. The order was approved by the Official Committee of Equity Security Holders in Sorrento's chapter 11 case.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
News
Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
dividends
Stock SRNEQ logo
Sorrento Therapeutics, Inc.

Nasdaq:SRNEQ

SRNEQ Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SRNEQ Stock Data

16.54M
538.99M
0.89%
0.07%
11.84%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
San Diego

About SRNEQ

sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.